Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number
CLEE11A2404 CompLEEment-1

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

Quantitative targeted proteomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing in Advanced Cancers

Site
Hackensack, Hackettstown

Sponsor
COTA/NANT Health

Protocol Number
COTA/NANT Health Pro2016-0817

To Learn More Call
201-510-0910

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Alliance Foundation

Protocol Number
AFT-05 PrECOG0109 PALLAS

Phase of Trial
Phase III

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1418

To Learn More Call
201-510-0910

A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Site
Sparta

Sponsor
Dompe

Protocol Number
REP0114

To Learn More Call
201-510-0910

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Sponsor
Novartis

Protocol Number